Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Work In Process (2016 - 2018)

Historic Work In Process for Anika Therapeutics (ANIK) over the last 8 years, with Q3 2018 value amounting to $5.9 million.

  • Anika Therapeutics' Work In Process fell 938.45% to $5.9 million in Q3 2018 from the same period last year, while for Sep 2018 it was $5.9 million, marking a year-over-year decrease of 938.45%. This contributed to the annual value of $6.1 million for FY2017, which is 904.84% up from last year.
  • According to the latest figures from Q3 2018, Anika Therapeutics' Work In Process is $5.9 million, which was down 938.45% from $6.3 million recorded in Q2 2018.
  • Anika Therapeutics' Work In Process' 5-year high stood at $6.6 million during Q3 2017, with a 5-year trough of $2.2 million in Q2 2014.
  • Moreover, its 5-year median value for Work In Process was $5.6 million (2016), whereas its average is $4.8 million.
  • Per our database at Business Quant, Anika Therapeutics' Work In Process skyrocketed by 9443.37% in 2016 and then crashed by 938.45% in 2018.
  • Quarter analysis of 5 years shows Anika Therapeutics' Work In Process stood at $3.0 million in 2014, then soared by 85.99% to $5.7 million in 2015, then decreased by 1.71% to $5.6 million in 2016, then rose by 9.05% to $6.1 million in 2017, then decreased by 1.88% to $5.9 million in 2018.
  • Its Work In Process stands at $5.9 million for Q3 2018, versus $6.3 million for Q2 2018 and $5.9 million for Q1 2018.